Treatment Goals
DHHS Last Updated: January 2016Australian Commentary Last Updated: July 2023 AU Comment: Treatment goals in Australia The principles of treatment goals of ART in Australia are consistent with DHHS recommendations, noting that in Australia both two and three drug ARV regimens are available. The principles of treatment goals of ART in Australia are consistent with […]
Initiation of Antiretroviral Therapy
DHHS Last Updated: December 2019Australian Commentary Last Updated: July 2023 Panel’s Recommendations Antiretroviral therapy (ART) is recommended for all persons with HIV to reduce morbidity and mortality (AI) and to prevent the transmission of HIV to others (AI). The Panel on Antiretroviral Guidelines for Adults and Adolescents recommends initiating ART immediately (or as soon as possible) after HIV […]
ART to Prevent Sexual Transmission of HIV
Antiretroviral Therapy to Prevent Sexual Transmission of HIV DHHS Last Updated: December 2019Australian Commentary Last Updated: July 2023 AU Comment: ART to prevent sexual transmission of HIV in the Australian context This guidance should be read in conjunction with ASHM’s U=U Guidance for Healthcare professionals, which defines an undetectable viral load as: two consecutive undetectable viral load […]
Initial Combination ARV Regimens for People with HIV
DHHS Last Updated: September 2024Australian Commentary Last Updated: December 2024 AU Comment: CAB-LA in Australia Long-acting cabotegravir (CAB-LA) for PrEP was TGA approved in 2022 but as of June 2024, the process for listing this medication on the PBS has ceased. However, some patients may have accessed CAB-LA as PrEP while overseas. Clinicians should ensure […]
Selecting an ART Regimen
Selecting an Antiretroviral Regimen DHHS Last Updated: September 2024 Australian Commentary Last Updated: December 2024 AU comment: CAB-LA in Australia Long-acting cabotegravir (CAB-LA) for PrEP was TGA approved in 2022 but as of June 2024 the process for listing this medication on the PBS has ceased. However, some patients may have accessed CAB-LA as PrEP […]
Nucleoside Reverse Transcriptase Inhibitor
Nucleoside Reverse Transcriptase Inhibitor Options as Part of Initial Therapy DHHS Last Updated: September 2024 Australian Commentary Last Updated: December 2024 The following sections provide detailed information on antiretroviral (ARV) drugs that the Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) recommends for initial therapy for most people with HIV and for initial therapy […]
Integrase Strand Transfer Inhibitor–Based Regimens
Integrase Strand Transfer Inhibitor–Based Regimens as Initial Antiretroviral Therapy DHHS Last Updated: September 2024 Australian Commentary Last Updated: December 2024 Table 8b. Characteristics of Integrase Strand Transfer Inhibitors That Are Recommended for Antiretroviral Therapy–Naive Patients BIC DTG Dosing Frequency Once daily Once daily As initial ART or in people with no INSTI-resistance mutations Twice Daily […]
Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens
Non-Nucleoside Reverse Transcriptase Inhibitor–Based Regimens as Initial Antiretroviral Therapy DHHS Last Updated: September 12, 2024 Australian Commentary Last Updated: December 2024 AU Comment: Efavirenz and nevirapine Efavirenz (EFV) is available under the PBS in Australia only as part of a generic single tablet regimen co-formulated with TDF/FTC. Nevirapine (NVP) 400mg modified release will no longer […]
Protease Inhibitor-Based Regimens
DHHS Last Updated: September 2024 Australian Commentary Last Updated: December 2024 Table 8d. Characteristics of Protease Inhibitor Options as Initial Antiretroviral Therapy in Certain Clinical Scenarios Characteristics DRV Dosing Frequency Once daily for persons with no prior PI experience. PK Boosting DRV should only be used with a PK booster (i.e., RTV or COBI). Fixed-Dose […]
Other ARV Regimens
Other Antiretroviral Regimens for Initial Therapy When Abacavir, Tenofovir Alafenamide, and Tenofovir Disoproxil Fumarate Cannot Be Used or Are Not Optimal DHHS Last Updated: September 2024 Australian Commentary Last Updated: December 2024 Most of the currently recommended antiretroviral (ARV) regimens for initial therapy consist of two nucleoside reverse transcriptase inhibitors (NRTIs) plus a third active […]